06:08 AM EST, 12/10/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said late Monday that a late-stage study of its experimental therapy, Carvykti, showed significantly improved minimal residual disease negativity rates in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior therapies.

The company said that in the study, patients treated with Carvykti had minimal residual disease negativity rates of 89%, which was more than double that of those receiving standard treatments.

It also said that at 2.5 years, patients with sustained minimal residual disease-negative complete response were 52% with Carvykti versus 10% with standard therapies.